Capstone Therapeutics Corp. (NASDAQ:CAPS) Sees Significant Drop in Short Interest

Posted by Casey Walker on Oct 30th, 2026

Capstone Therapeutics Corp. (NASDAQ:CAPS – Get Free Report) was the recipient of a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 696,378 shares, a drop of 65.6% from the September 30th total of 2,025,068 shares. Based on an average daily volume of 1,178,085 shares, the days-to-cover ratio is presently 0.6 days. Approximately 130.4% of the shares of the company are short sold.

Capstone Therapeutics Stock Down 18.7%

Capstone Therapeutics stock traded down $0.51 during trading on Friday, reaching $2.22. 105,667 shares of the company’s stock were exchanged, compared to its average volume of 92,384. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.39 and a current ratio of 0.99. The company’s 50-day moving average is $4.52 and its two-hundred day moving average is $11.09. The firm has a market cap of $1.95 million, a price-to-earnings ratio of -0.02 and a beta of -1.50. Capstone Therapeutics has a 52-week low of $2.11 and a 52-week high of $34.80.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Capstone Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 23rd. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Capstone Therapeutics currently has a consensus rating of “Sell”.

Read Our Latest Stock Report on Capstone Therapeutics

Capstone Therapeutics Company Profile

(Get Free Report)

Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury.

The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.